

## Special Issue

# Targeted Nanotherapy in Cancer Disease

### Message from the Guest Editors

Despite all the continuous efforts, cancer disease is a leading cause of death worldwide. In the last decades, the development of targeted therapeutics has revolutionized cancer therapy, with numerous formulations based on monoclonal antibodies, small molecule enzyme inhibitors, and recombinant proteins approved or under clinical trials for the treatment of several neoplasms. In certain types of carcinomas and advanced stages of the disease, chemotherapy constitutes a major treatment strategy, showing, in general, high toxicity. Their selective delivery to cancer cells may resolve this problem and increase the anticancer efficacy. In this way, several strategies have been used for this purpose, including the development of monoclonal-antibodies drug conjugates or the use of nanocarriers coated with ligands specifically recognized by cancer cells. In the present Special Issue, studies reporting original data or updated literature reviews concerning targeted chemonanotherapy are welcome.

---

### Guest Editors

Prof. Dr. Donatella Paolino

Dr. Ana Isabel Fraguas-Sánchez

Dr. Cristina Martin-Sabroso

---

### Deadline for manuscript submissions

closed (20 January 2022)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/76046](https://mdpi.com/si/76046)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).